.On the same day that some Parkinson’s disease medications are actually being actually brought into question, AbbVie has declared that its late-stage monotherapy applicant has
Read moreAZ licenses thrown away uncommon condition medicine to Monopar Therapeutics
.Monopar Rehabs is bouncing back a medication from the dump of AstraZeneca’s rare illness pipe. It has actually accredited ALXN-1840, a prospect for the procedure
Read moreAZ details AI-enabled TROP2 biomarker approach for Daiichi ADC
.AstraZeneca has used expert system to develop an one-of-a-kind biomarker for its own Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), intending to separate the antibody-drug conjugate (ADC)
Read more